Navigation Links
Perrigo Company Appointed Generic Distributor by Medimetriks Pharmaceuticals
Date:1/26/2009

FAIRFIELD, N.J., Jan. 26 /PRNewswire/ -- Medimetriks Pharmaceuticals announced today that the Company has entered into a Distributor Agreement with Perrigo Company (Nasdaq: PRGO), a leading manufacturer in the generic prescription marketplace, designating Perrigo as the Exclusive Authorized Distributor of generic versions of Medimetriks' branded products in the U.S. The agreement calls for Medimetriks to receive a percentage of Perrigo's Net Sales on the non-branded products, allowing Medimetriks to maximize its investment in its brands and maintain a revenue stream from the markets these brands create.

Founded in May, 2008, Medimetriks launched its first prescription brands in the 4th Quarter of 2008 to the Dermatology and Podiatry markets. These brands include Pacnex(TM) (7% Benzoyl Peroxide) Wash, a topical treatment for acne in a unique vehicle containing Aloe and Green Tea; Sumaxin(TM) (Sodium sulfacetamide 10% & sulfur 4%) Cleansing Pads, a topical treatment for acne and rosacea also in a vehicle containing Aloe and Green Tea; and Uramaxin(TM) (45% Urea) Nail Gel, a treatment for diseased and damaged nails in a unique vehicle containing Menthol, Camphor and Eucalyptus Oil. The agreement also includes future products launched by Medimetriks.

"Our agreement with Perrigo represents a strategic opportunity for Medimetriks to leverage our brand assets in the non-branded marketplace," stated Bradley Glassman, President and CEO of Medimetriks. "We are pleased to work with one of the world's leading healthcare manufacturers and generic marketers, with a particular expertise in the topical generic market."

"We believe our relationship with Medimetriks will be a mutually beneficial one," stated Sharon Kochan, Executive Vice President of Perrigo. "Medimetriks' Management Team, having previously built Bradley Pharmaceuticals into an approximately $200 million gross revenue company, has a solid track record of success in building a branded pharmaceutical business in the markets they serve."

About Medimetriks Pharmaceuticals, Inc.

Medimetriks Pharmaceuticals develops, licenses and commercializes prescription skincare products primarily for the Dermatology and Podiatry marketplaces. The Company's mission is to enhance patient quality-of-life by providing innovative therapies that advance patient care.

The Company is located at 363 Route 46 West, Fairfield, NJ 07004-2402. Please visit the Medimetriks website at www.medimetriks.com, call (973) 882-7512 or fax (973) 882-7502.

Pacnex(TM) Wash is for external use only. Avoid contact with eyes, lips or mucous membranes. If severe irritation develops, discontinue use of Pacnex(TM) Wash. While using Pacnex(TM) Wash, patients should be advised to avoid unnecessary sun exposure. Please see full Prescribing Information available at www.medimetriks.com.

Sumaxin(TM) Cleansing Pads are contraindicated in persons with known or suspected hypersensitivity to sulfonamides or sulfur. Sumaxin(TM) Cleansing Pads are not to be used by patients with kidney disease. Although rare, topical sodium sulfacetamide may cause local irritation. Please see full Prescribing Information available at www.medimetriks.com.

Uramaxin(TM) Nail Gel is for external use only. Avoid contact with eyes, lips or mucous membranes. Transient stinging, burning, itching or irritation may occur and normally disappear on discontinuing the medication. Use as directed. Please see full Prescribing Information available at www.medimetriks.com.


'/>"/>
SOURCE Medimetriks Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Perrigo Company Will Release Second Quarter Fiscal Year 2009 Results on February 3, 2009
2. Perrigo Company to Present at the 27th Annual JPMorgan Healthcare Conference
3. Perrigo Announces FDA Final Approval for Ibuprofen PM
4. Perrigo Settles Desloratadine Patent Litigation
5. Perrigo Acknowledges Settlement of NASACORT(R) AQ Nasal Spray Patent Litigation
6. Perrigo Announces FDA Tentative Approval for Ibuprofen PM
7. Perrigo Company Licenses Prescription Brands to Medimetriks Pharmaceuticals
8. Perrigo Company To Present at the Merrill Lynch Global Pharmaceutical Conference
9. Perrigo Begins Shipments of Famotidine Complete to Customers Nationwide
10. Perrigo Company Announces Appointment of New Board Member
11. Perrigo Company to Present at The Oppenheimer & Co. Inc. 8th Annual Consumer Growth Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... ... February 10, 2016 , ... Anxiety of older Americans over ... of Medicare Part D a decade ago, according to The Senior Citizens League ... on how they are coping with rapidly rising costs. “The implications are chilling, ...
(Date:2/10/2016)... ... February 09, 2016 , ... According to a recent ... dramatic increase in the number of patients under the age of 30. According to ... seeing in their offices, and may indicate an overall shift in the rapidly growing ...
(Date:2/9/2016)... Nevada (PRWEB) , ... February 09, 2016 , ... ... providing treatment to Medicaid beneficiaries who are diagnosed with autism spectrum disorder (ASD). ... Nevada. Autism treatment using applied behavior analysis (ABA) is key to providing ...
(Date:2/9/2016)... ... February 09, 2016 , ... ... compensation fee schedule rates and Medicare rates for a variety of medical services ... report, Evaluation of the 2015 Fee Schedule Rates in Illinois, are ...
(Date:2/9/2016)... NY (PRWEB) , ... February 09, 2016 , ... Establishment ... appointment of Dr. David Hung to the company´s Board of Directors. , ... world class scientist and an exceptional entrepreneur.” said Juan Jose Chacon Quiros, CEO of ...
Breaking Medicine News(10 mins):
(Date:2/9/2016)... 2016  Increasingly, health care professionals are enhancing patient ... wireless technology. With the Vios Monitoring System from Vios ... remotely detect problems before they become serious by continuously ... the United States . ... --> The Vios Monitoring System connects ...
(Date:2/9/2016)... Feb. 9, 2016  Johnson & Johnson (NYSE: ... Global Healthcare Conference on Tuesday, Feb. 23, at the ... Caruso , Vice President, Finance & Chief Financial Officer ... represent the Company in a session scheduled at 10:00 ... --> www.investor.jnj.com . --> This webcast ...
(Date:2/9/2016)... , Feb. 9, 2016 Athenex, Inc. announced ... as Vice President of Corporate Strategy and Business Development based ... MBA has joined as Senior Director and Deputy Head of Clinical Research ... . Simon Pedder stated, "Athenex has a ... a while. Coupled together with their unique business model and ...
Breaking Medicine Technology: